Clinical Trial Update: Study on the Mechanism of Acquired Resistance of Entrectinib

View source ↗

Summary

A clinical trial update from Fudan University studying how resistance to entrectinib develops in ROS1 fusion-positive non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Rozlytrek (entrectinib)

Snippet

Sponsor: Fudan University | Conditions: ROS1 Fusion Positive, Non Small Cell Lung Cancer | Status: RECRUITING